USE OF 2-METHYLENE-19-NOR-20(S)-1 alpha ,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH

摘要

This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment of diseases where bone formation is desired, particularly osteoporosis. This compound also exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anticancer agent and for the treatment of skin diseases such as psoriasis. This compound also increases both breaking strength and crushing strength of bones eveidencing use in conjunction with boen replacement surgery such as hip and knee replacements.